ABT-639
目录号: PL04927 纯度: ≥98%
CAS No. :1235560-28-7
商品编号 规格 价格 会员价 是否有货 数量
PL04927-5mg 5mg ¥1607.27 请登录
PL04927-10mg 10mg ¥2720.00 请登录
PL04927-25mg 25mg ¥5316.36 请登录
PL04927-50mg 50mg ¥8530.91 请登录
PL04927-100mg 100mg ¥13847.27 请登录
PL04927-200mg 200mg 询价 询价
PL04927-500mg 500mg 询价 询价
PL04927-10mM*1mLinDMSO 10mM*1mLinDMSO ¥1768.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
ABT-639
中文别名
4-氯-2-氟-N-(2-氟苯基)-5-[[(8aR)-六氢吡咯并[1,2-a]吡嗪-2(1H)-基]羰基]苯磺酰胺
英文名称
ABT-639
英文别名
ABT 639;ABT-639;0G7D0CQ88I;ABT639;(R)-4-Chloro-2-fluoro-N-(2-fluorophenyl)-5-(octahydropyrrolo[1,2-a]pyrazine-2-carbonyl)benzenesulfonamide;4-chloro-2-fluoro-N-(2-fluorophenyl)-5-[[(8aR)-hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]carbonyl]benzenesulfonamide;5-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine-2-carbonyl]-4-chloro-2-fluoro-N-(2-fluorophenyl)benzenesulfonamide;GTPL7721;BCP17732;BDBM
Cas No.
1235560-28-7
分子式
C20H20ClF2N3O3S
分子量
455.91
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
ABT-639 是一种新型选择性的 T 型 Ca2+ 通道阻滞剂。
生物活性
ABT-639 is a novel, peripherally acting, selective T-type Ca channel blocker.
性状
Solid
IC50 & Target[1][2]
Ca Channel
体内研究(In Vivo)
ABT-639 blocks recombinant human T-type (Ca v 3.2) Ca channels in a voltage-dependent fashion (IC 50 =2 μM) and attenuates low voltage-activated (LVA) currents in rat DRG neurons (IC 50 =8 μM). ABT-639 is significantly less active at other Ca channels (e.g. Ca v 1.2 and Ca v 2.2) (IC 50 >30 mM). ABT-639 has high oral bioavailability (%F=73), low protein binding (88.9%) and a low brain:plasma ratio (0.05:1) in rodents. Following oral administration ABT-639 produces dose-dependent antinociception in a rat model of knee joint pain (ED 50 =2 mg/kg, p.o.). ABT-639 (10-100 mg/kg, p.o.) also increases tactile allodynia thresholds in multiple models of neuropathic pain (e.g. spinal nerve ligation, CCI, and vincristine-induced, and capsaicin secondary hypersensitivity). ABT-639 does not attenuate hyperalgesia in inflamma
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Jarvis MF, et al. A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochem Pharmacol. 2014 Jun 15;89(4):536-44.
溶解度数据
In Vitro: DMSO : 10 mg/mL (21.93 mM; Need ultrasonic and warming)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2